Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of experts

Moos, Roger von; Thuerlimann, Beat; Aapro, Matti; Rayson, Daniel; Harrold, Karen; Sehouli, Jalid; Scotté, Florian; Lorusso, Domenica; Dummer, Reinhard; Lacouture, Mario E.; Lademann, Jürgen; Hauschild, Axel

doi:10.1016/j.ejca.2008.01.028

Cited by 113 publications

(75 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It seems necessary to develop a health-related QoL scale enabling investigators to independently assess the effects of anticancer treatment and the effects of the cancer itself on QoL. Besides, additional research is needed to determine to what extent HFS prevention and treatment strategies could alter the QoL of cancer patients with HFS [10,11,14].…”

Section: Discussionmentioning

confidence: 99%

“…Several experts highlighted the importance of properly assessing QoL in combination with therapeutic efficacy to help determine the most effective HFS management strategies in patients treated for cancer [9,10,11,14]. If appropriate management is not rapidly implemented, HFS may worsen and QoL impairment may lead to anticancer treatment modification or discontinuation, with the risk for potentially limiting its efficacy [3,23].…”

Section: Discussionmentioning

confidence: 99%

“…Most reports have indicated that severe HFS could lead to significant morbidity and poor patient compliance with cancer treatment [11]. Currently available QoL measurement tools such as the Skindex-16 [12] and the Dermatology Life Quality Index (DLQI) questionnaire [13] can assess skin-related QoL in patients receiving chemotherapy or MKIs [10], but they are not specifically designed for this population [14].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand–Foot Syndrome

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand–Foot Syndrome

et al. 2011

View full text Add to dashboard Cite

show abstract

“…However, in clinical practice the administration of PEGylated liposomes loaded with doxorubicin was associated with palmar-plantar erythrodysesthesia ("hand-foot" syndrome), which may evolve into ulceration and epidermal necrosis if the chemotherapy cycle is not delayed (19). Hand-foot syndrome represents a major limitation in the Caelyx treatment, because it can adversely affect the quality of life of the patients, which may be addressed by dose-reduction strategy (20). In addition, recent studies have demonstrated that PEGylated liposomes can generate complement activation through increased alternative pathway turnover (21), which now provides a plausible explanation to the previously reported anaphylaxis, or is referred to as cardiovascular collapse in species that have received medicines containing poly (ethylene glycol) as a carrier/solubilizer (22).…”

Section: Significancementioning

confidence: 99%

A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity

Maksimenko

Dosio

Mougin

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

186

163

View full text Add to dashboard Cite

We identified that the chemical linkage of the anticancer drug doxorubicin onto squalene, a natural lipid precursor of the cholesterol's biosynthesis, led to the formation of squalenoyl doxorubicin (SQ-Dox) nanoassemblies of 130-nm mean diameter, with an original "loop-train" structure. This unique nanomedicine demonstrates: (i) high drug payload, (ii) decreased toxicity of the coupled anticancer compound, (iii) improved therapeutic response, (iv) use of biocompatible transporter material, and (v) ease of preparation, all criteria that are not combined in the currently available nanodrugs. Cell culture viability tests and apoptosis assays showed that SQ-Dox nanoassemblies displayed comparable antiproliferative and cytotoxic effects than the native doxorubicin because of the high activity of apoptotic mediators, such as caspase-3 and poly(ADPribose) polymerase. In vivo experiments have shown that the SQDox nanomedicine dramatically improved the anticancer efficacy, compared with free doxorubicin. Particularly, the M109 lung tumors that did not respond to doxorubicin treatment were found inhibited by 90% when treated with SQ-Dox nanoassemblies. SQ-Dox nanoassembly-treated MiaPaCa-2 pancreatic tumor xenografts in mice decreased by 95% compared with the tumors in the saline-treated mice, which was significantly higher than the 29% reduction achieved by native doxorubicin. Concerning toxicity, SQ-Dox nanoassemblies showed a fivefold higher maximum-tolerated dose than the free drug, and moreover, the cardiotoxicity study has evidenced that SQ-Dox nanoassemblies did not cause any myocardial lesions, such as those induced by the free doxorubicin treatment. Taken together, these findings demonstrate that SQ-Dox nanoassemblies make tumor cells more sensitive to doxorubicin and reduce the cardiac toxicity, thus providing a remarkable improvement in the drug's therapeutic index.squalene-doxorubicin bioconjugate | pancreatic cancer | lung cancer

show abstract

“…Some of these agents including celecoxib have demonstrated promising effects in subsets of patients [17], but require further research to substantiate preliminary findings. Research in non-pharmacologic intervention for the prevention or treatment of HFS is limited, resulting in an inability to establish effectiveness [18].…”

Section: Introductionmentioning

confidence: 99%

Relationship between Self-Care and Hand Foot Syndrome Specific Quality of Life in Cancer Patients

Mikoshiba¹,

Yamamoto‐Mitani²,

Sato³

et al. 2016

OJN

View full text Add to dashboard Cite

Purpose: The purpose of this study was to describe adherence to self-care for hand-foot syndrome (HFS) and the relationship between self-care and health-related quality of life (QOL). Methods: A cross-sectional study was conducted on 105 consecutive outpatients with HFS. To assess self-care for HFS and QOL, the participants were asked to complete self-care and HFS-14 (hand-foot syndrome specific QOL) questionnaires, respectively. Multiple regression models were used to identify the relationship between self-care and QOL. Results: Adherence to self-care for HFS was low, less than 50% for most of the items. Multivariate analysis revealed that poorer self-care (βs = −0.19; P = 0.03), depressive symptoms (βs = 0.43; P < 0.0001), and being employed (βs = 0.20; P = 0.04) were independent predictors of poorer QOL scores. Conclusions: We have identified a need for further research to develop effective programs of self-care in HFS.

show abstract

Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of experts

Cited by 113 publications

References 50 publications

HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand–Foot Syndrome

HFS-14, a Specific Quality of Life Scale Developed for Patients Suffering from Hand–Foot Syndrome

A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity

Relationship between Self-Care and Hand Foot Syndrome Specific Quality of Life in Cancer Patients

Contact Info

Product

Resources

About